Supplements
ESCRS Clinical Trends Survey 2019 Results
Colin Kerr
Published: Thursday, November 5, 2020
This report contains the results of the 2019 ESCRS Clinical Trends Survey, conducted at the 37th ESCRS Congress in Paris, France. Delegates also had the option of taking the survey online at the ESCRS website. Questions addressed several areas of clinical practice, including general cataract surgery, astigmatism and toric IOLs, presbyopia correction, glaucoma and ocular surface disease. More than 2,100 doctors responded to 156 questions, which were developed and reviewed with the ESCRS leadership and substantiated by a data scientist. The survey results help ESCRS to better identify the educational needs of its members and the ESCRS leadership continually refers to the results of the annual surveys and the feedback they elicit. The collected data also enhances the education featured at the ESCRS Annual Congress, the ESCRS Winter Meeting and other educational channels, such as EuroTimes articles and online forums. We invite you to study the survey’s key findings and be ready to take advantage of upcoming educational events. ESCRS encourages all delegates to participate in the 2020 ESCRS Clinical Trends Survey here.
Latest Articles
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.